Biosimilar Buyouts: AbbVie Buyout of Allergan Receives Approval of Irish High Court; Gedeon Richter Buys Tocilizumab Biosimilar

Goodwin
Contact

Goodwin

On May 8, 2020, AbbVie announced that it completed its acquisition of Allergan plc, having received approval by the Irish High Court.  AbbVie and Allergan had previously announced, on May 5, 2020, that the U.S. Federal Trade Commission accepted the proposed consent order in connection with the acquisition.  As part of the consent order, Allergan agreed to divest brazikumab, a monoclonal antibody that binds to the IL23 receptor and is in development for Crohn’s Disease and Ulcerative Colitis, to AstraZeneca.

In other news, last week Taiwan-based Mycenax announced plans to sell its tocilizumab biosimilar, LusiNEX, to Hungary-based Gedeon Richter for $16.5 million.  LusiNEX, which has been in development since 2013, is currently being tested in a phase 1 trial. The proposed biosimilar is intended for second-line treatment of rheumatoid arthritis, but the FDA has approved a phase 3 trial to investigate the safety and efficacy of LusiNEX in treating COVID-19 pneumonia.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.